Silkworm model of biofilm formation: In vivo evaluation of antimicrobial tolerance of a cross-kingdom dual-species (Escherichia coli and Candida albicans) biofilm on catheter material

Biofilms are formed by microorganisms and their products on the surface of materials such as medical devices. Biofilm formation protects microorganisms from antimicrobial agents. Bacteria and fungi often form dual-species biofilms on the surfaces of medical devices in clinical settings. An experimental system to evaluate in vivo biofilm formation by the pathogenic fungus Candida albicans was established using silkworms inserted with polyurethane fiber (PF), a catheter material. In the present study, we established an in vivo experimental system using silkworms to evaluate the antimicrobial tolerance of Escherichia coli in single- and dual-species biofilms formed on the surface of the PF. The injection of E. coli into the PF-inserted silkworms led to the formation of a biofilm by E. coli on the surface of the PF. E. coli in the biofilm exhibited tolerance to meropenem (MEPM). Furthermore, when E. coli and C. albicans were co-inoculated into the PF-inserted silkworms, a dual-species biofilm formed on the surface of the PF. E. coli in the dual-species biofilm with C. albicans was more tolerant to MEPM than E. coli in the single-species biofilm. These findings suggest the usefulness of an in vivo experimental system using PF-inserted silkworms to investigate the mechanisms of MEPM tolerance in E. coli in single- and dual-species biofilms.

[1]  T. Sugita,et al.  Candida albicans Promotes the Antimicrobial Tolerance of Escherichia coli in a Cross-Kingdom Dual-Species Biofilm , 2022, Microorganisms.

[2]  C. Cho,et al.  Progress of Polysaccharide-Contained Polyurethanes for Biomedical Applications , 2022, Tissue Engineering and Regenerative Medicine.

[3]  A. Raghu,et al.  A microplate‐based Response Surface Methodology model for growth optimization and biofilm formation on polystyrene polymeric material in a Candida albicans and Escherichia coli co‐culture , 2022, Polymers for Advanced Technologies.

[4]  K. Shetty,et al.  Polymicrobial Biofilm Dynamics of Multidrug-Resistant Candida albicans and Ampicillin-Resistant Escherichia coli and Antimicrobial Inhibition by Aqueous Garlic Extract , 2022, Antibiotics.

[5]  I. Dag,et al.  In vitro effect of farnesol on planktonic cells and dual biofilm formed by Candida albicans and Escherichia coli , 2022, Biofouling.

[6]  K. Shetty,et al.  High throughput comparative assessment of biofilm formation of Candida glabrata on polystyrene material , 2022, Korean Journal of Chemical Engineering.

[7]  K. Shetty,et al.  Candida albicans biofilm formation and growth optimization for functional studies using response surface methodology , 2021, Journal of applied microbiology.

[8]  E. D. Di Domenico,et al.  The Impact of Bacterial Biofilms on End-Organ Disease and Mortality in Patients with Hematologic Malignancies Developing a Bloodstream Infection , 2021, Microbiology spectrum.

[9]  T. Sugita,et al.  Pharmacokinetics of voriconazole and its alteration by Candida albicans infection in silkworms , 2021, The Journal of Antibiotics.

[10]  J. Naglik,et al.  Candida albicans biofilms and polymicrobial interactions , 2021, Critical reviews in microbiology.

[11]  G. Maisetta,et al.  Therapeutic Potential of Antimicrobial Peptides in Polymicrobial Biofilm-Associated Infections , 2021, International journal of molecular sciences.

[12]  T. Sugita,et al.  Evaluating Candida albicans biofilm formation in silkworms. , 2020, Medical mycology.

[13]  C. Kaito,et al.  Animal infection models using non‐mammals , 2020, Microbiology and immunology.

[14]  E. Denamur,et al.  Mortality in Escherichia coli bloodstream infections: antibiotic resistance still does not make it. , 2020, The Journal of antimicrobial chemotherapy.

[15]  S. Auparakkitanon,et al.  Clinical outcomes of empirical high-dose meropenem in critically ill patients with sepsis and septic shock: a randomized controlled trial , 2020, Journal of Intensive Care.

[16]  Yasuhiko Matsumoto Facilitating Drug Discovery in Human Disease Models Using Insects. , 2020, Biological & pharmaceutical bulletin.

[17]  R. Hall,et al.  Candida albicans enhances meropenem tolerance of Pseudomonas aeruginosa in a dual-species biofilm , 2019, The Journal of antimicrobial chemotherapy.

[18]  K. Sekimizu,et al.  Pharmacokinetics of anti-infectious reagents in silkworms , 2019, Scientific Reports.

[19]  K. Sekimizu,et al.  Silkworm as an experimental animal for research on fungal infections , 2019, Microbiology and immunology.

[20]  M. Ghannoum,et al.  Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms , 2018, Microbial cell.

[21]  Peter Belenky,et al.  Microbial competition between Escherichia coli and Candida albicans reveals a soluble fungicidal factor , 2018, Microbial cell.

[22]  K. Sekimizu,et al.  Pharmacokinetic parameters explain the therapeutic activity of antimicrobial agents in a silkworm infection model , 2018, Scientific Reports.

[23]  J. Nett,et al.  The Interface between Fungal Biofilms and Innate Immunity , 2018, Front. Immunol..

[24]  F. Contaldo,et al.  Central venous catheter related bloodstream infections in adult patients on home parenteral nutrition: Prevalence, predictive factors, therapeutic outcome. , 2016, Clinical nutrition.

[25]  P. van Dijck,et al.  Commensal Protection of Staphylococcus aureus against Antimicrobials by Candida albicans Biofilm Matrix , 2016, mBio.

[26]  K. Sekimizu,et al.  Discovery of a new antifungal agent ASP2397 using a silkworm model of Aspergillus fumigatus infection , 2016, The Journal of Antibiotics.

[27]  D. Soll,et al.  Plasticity of Candida albicans Biofilms , 2016, Microbiology and Molecular Reviews.

[28]  J. Nett The Host’s Reply to Candida Biofilm , 2016, Pathogens.

[29]  K. Sekimizu,et al.  Acute oral toxicity test of chemical compounds in silkworms. , 2016, Drug discoveries & therapeutics.

[30]  M. Doble,et al.  Bacterial resistance in biofilm-associated bacteria. , 2015, Future microbiology.

[31]  E. Mylonakis,et al.  Impact of a Cross-Kingdom Signaling Molecule of Candida albicans on Acinetobacter baumannii Physiology , 2015, Antimicrobial Agents and Chemotherapy.

[32]  J. Bernhardt,et al.  Host Contributions to Construction of Three Device-Associated Candida albicans Biofilms , 2015, Infection and Immunity.

[33]  Yue Zheng,et al.  Biofilm formation mechanisms and targets for developing antibiofilm agents. , 2015, Future medicinal chemistry.

[34]  J. Chander,et al.  Incidence, risk factors, microbiology of venous catheter associated bloodstream infections - A prospective study from a tertiary care hospital , 2015, Indian journal of medical microbiology.

[35]  N. Verstraeten,et al.  Fungal β-1,3-Glucan Increases Ofloxacin Tolerance of Escherichia coli in a Polymicrobial E. coli/Candida albicans Biofilm , 2015, Antimicrobial Agents and Chemotherapy.

[36]  H. Kurihara,et al.  Lysocin E is a new antibiotic that targets menaquinone in the bacterial membrane. , 2015, Nature chemical biology.

[37]  David Lebeaux,et al.  Biofilm-Related Infections: Bridging the Gap between Clinical Management and Fundamental Aspects of Recalcitrance toward Antibiotics , 2014, Microbiology and Molecular Reviews.

[38]  A. Walker,et al.  Increasing incidence of Escherichia coli bacteraemia is driven by an increase in antibiotic-resistant isolates: electronic database study in Oxfordshire 1999-2011. , 2012, The Journal of antimicrobial chemotherapy.

[39]  E. Denamur,et al.  Host Factors and Portal of Entry Outweigh Bacterial Determinants To Predict the Severity of Escherichia coli Bacteremia , 2010, Journal of Clinical Microbiology.

[40]  H. Flemming,et al.  The biofilm matrix , 2010, Nature Reviews Microbiology.

[41]  P. Lipke,et al.  Polymicrobial bloodstream infections involving Candida species: analysis of patients and review of the literature. , 2007, Diagnostic microbiology and infectious disease.

[42]  M. Ghannoum,et al.  Rabbit Model of Candida albicans Biofilm Infection: Liposomal Amphotericin B Antifungal Lock Therapy , 2004, Antimicrobial Agents and Chemotherapy.

[43]  H. Kusuhara,et al.  Quantitative Evaluation of the Therapeutic Effects of Antibiotics Using Silkworms Infected with Human Pathogenic Microorganisms , 2004, Antimicrobial Agents and Chemotherapy.

[44]  D. Davies,et al.  Understanding biofilm resistance to antibacterial agents , 2003, Nature Reviews Drug Discovery.

[45]  R. Donlan,et al.  Biofilms: Microbial Life on Surfaces , 2002, Emerging infectious diseases.

[46]  Haruo Watanabe,et al.  Silkworm larvae as an animal model of bacterial infection pathogenic to humans. , 2002, Microbial pathogenesis.

[47]  N. Khardori,et al.  Biofilms in device-related infections , 1995, Journal of Industrial Microbiology.

[48]  G. O’Toole,et al.  Mechanisms of biofilm resistance to antimicrobial agents. , 2001, Trends in microbiology.

[49]  N. Webber,et al.  Association between atherosclerosis and osteoporosis, the role of vitamin D , 2011, Archives of medical science : AMS.